A comparison of the efficacy and tolerability of treating primary nocturnal enuresis with Solifenacin Plus Desmopressin, Tolterodine Plus Desmopressin, and Desmopressin alone: a randomized controlled clinical trial

What Was Tested

The paper reports a study of Vasopressin and Desmopressin, published as a randomized controlled trial.

Because the researchers don't have enough information about this comparison especially about solifenacin plus desmopressin.

Why It Was Studied

Nocturnal enuresis (enuresis) is one of the most common developmental problems of childhood, which has often a familial basis, causes mental and psychological damage to the child and disrupts family solace.

Who Took Part

The abstract describes 62 patients taking part.

The age groups tagged for this paper are young children, children and teenagers.

This clinical trial study was performed on 62 patients with enuresis aged 5-15 years who referred to the urology clinic of Imam Khomeini Hospital in Ahwaz in 2017-2018.

Patients were randomly assigned to one of the three different therapeutic protocols and any participants were given a specific code.

How the Study Was Run

The design is described as randomized.

Random assignment meant chance, not the researchers, decided who got Vasopressin and who got the comparison, which limits bias.

After that, the researchers compared the therapeutic response and the level of satisfaction of each therapeutic group in different months.

Data were analyzed using SPSS 22 software and descriptive and analytical statistics.

What Was Measured

Topics PubMed links to this paper include Cholinergic Antagonists, Deamino Arginine Vasopressin, Enuresis, Nocturnal Enuresis, Solifenacin Succinate and Tolterodine Tartrate.

Author keywords: desmopressin, valyl(4)-glutaminyl(5)- [Supplementary Concept].

What This Means in Plain Language

The paper is a randomized study of Vasopressin and Desmopressin in 62 patients.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2021 (International braz j urol : official journal of the Brazilian Society of Urology), a journal based in Brazil.

More context: the Vasopressin compound page and the Desmopressin compound page, all human trials.